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Abstract
Background: Although tumor-associated macrophages (TAMs) are essential for cancer progression, connections
between different clinical outcomes and transcriptional networks have not been reported. We have addressed this
issue by analyzing global expression patterns of TAMs isolated from the ascites of ovarian cancer patients.
Results: TAMs isolated from different ovarian cancer patients can be stratified by coexpression or principal component
analysis into subgroups with specific biological features and associated with distinct clinical outcomes. A hallmark of
subgroup A is a high expression of clinically unfavorable markers, including (i) high CD163 expression, a surface receptor
characteristic of an anti-inflammatory activation state, (ii) increased PCOLCE2 expression, indicative of enhanced
extracellular matrix organization, and (iii) elevated ascites levels of IL-6 and IL-10, linked to the aggressiveness of
ovarian cancer and immune suppression. In contrast, subgroup B TAMs are characterized by the upregulation of
genes linked to immune defense mechanisms and interferon (IFN) signaling. Intriguingly, analysis of published
data for 1763 ovarian cancer patients revealed a strong association of this transcriptional signature with a longer
overall survival. Consistent with these results, IFNγ was able to abrogate the suppressive effect of ovarian cancer
ascites on the inducibility of IL12B expression and IL-12 secretion, a key determinant of a cytotoxic immune response.
Conclusions: The survival of ovarian cancer patients is linked to the presence of TAMs with a transcriptional signature
that is characterized by a low expression of protumorigenic and immunosuppressive markers and an upregulation of
genes linked to interferon signaling. The observed IFNγ-mediated restoration of the inducibility of IL-12 in the presence
of ascites provides a possible explanation for the association of an interferon signaling-associated signature with
a favorable clinical outcome.
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Background
Ovarian tumors ranks fifth as the cause of cancer-
related death in women and represents the deadliest of
all gynecological tumors [1, 2]. More than 90% of
ovarian cancers are carcinomas that originate from the
ovarian surface or fallopian tube epithelium. High grade
serous adenocarcinoma is the most common ovarian
carcinoma subtype, with most patients presenting with
advanced stage disease and disseminated tumor masses
at the time of diagnosis. Although most ovarian cancers
are highly sensitive to first-line adjuvant chemotherapy,
the disease has a dire prognosis with an overall 5-year
survival rate of less than 40% [1, 2]. Several characteris-
tic features contribute to the fatal nature of high grade
serous ovarian adenocarcinoma, including the shedding
of tumor cells at a very early stage of the disease, their
spreading via the peritoneal fluid to form transcoelomic
metastases and the tumor-promoting and immune sup-
pressive effect of the peritoneal tumor environment,
frequently formed by the malignancy-associated effu-
sion within the peritoneal cavity, commonly referred to
as malignant ascites. This tumor microenvironment,
consisting to a large extent of host-derived cells, is cru-
cial for the growth, progression, therapy resistance and
immune escape of malignant tumors, including ovarian
cancer [3].
The most common cell types in ovarian HGSC-
associated ascites are macrophages and T lymphocytes
[3]. Tumor-associated macrophages (TAMs) can be
derived from both blood monocytes [4–6] or resident
tissue macrophages [7–13], with the latter most likely
representing the major origin of TAMs in ovarian cancer
[14]. TAM activation is skewed by factors of the tumor
microenvironment to adopt a spectrum of phenotypes
that represent mixed forms of alternatively activated
(immune regulatory) and pro-inflammatory macro-
phages [15], which has also been clearly demonstrated
for TAMs in ovarian cancer ascites [16]. TAMs do not
possess tumoricidal activity, but are rather thought to
promote immune suppression and various aspects of
cancer growth and progression, including tumor cell in-
vasion, angiogenesis and metastasis [15]. Consistent with
these tumor-promoting functions of TAMs, expression
of the alternative activation marker CD163 in TAMs
from malignancy-associated ascites showed a strong cor-
relation with early relapse of serous ovarian carcinoma
after first-line therapy [16]. Among the soluble factors
contributing to TAM polarization, tumor progression
and a poor clinical outcome, interleukin 10 (IL-10), IL-6,
transforming growth factor β (TGFβ) and arachidonic
acid play a prominent role [14, 16–20].
To date, transcriptional signatures of human TAMs
that distinguish subgroups of patients have not been
described. In the present study, we address this issue by
determining the transcriptome of TAMs from different
patients in conjunction with principal component ana-
lysis (PCA) and coexpression analysis to define distinct
subgroups. These analyses lead to the identification of
two subgroups differing in the expression of genes as-
sociated with cytokine signaling, immune regulation,
extracellular matrix reorganization and overall survival.
Of note, an interferon (IFN) related signature showed a
striking association with a favorable clinical outcome.
Furthermore, IFNγ counteracted repression by ovarian
cancer ascites of IL-12, a key mediator of an anti-tumor
response mediated by natural killer cells (NK) and T
lymphocytes, consistent with the observed association
of an IFN signaling-associated signature with ovarian
cancer survival.
Methods
Patient samples
Ascites was collected from patients undergoing primary
surgery at the University Hospital in Marburg. Patient
characteristics are presented in Additional file 1: Table S1.
Isolation and immunophenotyping of cells from ovarian
cancer ascites
Mononuclear cells were isolated from ascites by
Lymphocyte Separation Medium 1077 (PromoCell)
density gradient centrifugation and further purified by
magnetic cell sorting (MACS) using CD14 microbeads
(Miltenyi Biotech) [16]. TAMs were analyzed by flow
cytometry for surface expression of CD14, CD16,
CD32, CD64, CD163 and CD206 as described [16].
Tumor cell spheroids and T cells were analyzed as pre-
viously published [21].
Isolation and culture of monocyte-derived macrophages
Monocyte-derived macrophages (MDMs) were generated
from monocytes (6-day differentiation period) from
healthy donors as described [22] and cultured in RPMI
medium with 5% human male AB serum (Sigma-Aldrich,
Taufkirchen, Germany) or cell-free ascites from ovarian
cancer patients, as indicated. T cell from peripheral blood
were isolated as described for ascites [21]. Buffy coats
were obtained from the blood bank at UKGM Giessen,
Germany.
RT-qPCR
Isolation of RNA and RT-qPCR were carried out as
described [23]. The following primers were used:
RPL27_fw: 5′AAAGCTGTCATCGTGAAGAAC
RPL27_rv: 5′GCTGTCACTTTGCGGGGGTAG
IL12B_fw: 5′GCGAGGTTCTAAGCCATTCG
IL12B_rev: 5′ACTCCTTGTTGTCCCCTCTG
CXCL10_fw: 5′AAGCAGTTAGCAAGGAAAGGTC
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CXCL10_rv: 5′GACATATACTCCATGTAGGGAA
GTGA
GBP4_fw: 5′TTCAAAGGCATTAGAGATTCTTGA
GBP4_rv: 5′GTGGAGCCCAGAGGGAAG
GPNMB_fw: 5′CTATGAGAAGAACTGCAGAAATG
GPNMB_rv: 5′GTTATGATGGCTTTGGCCGG
LGALS2_fw: 5′CCACGAGTTGAGCCCTGAG
LGALS2_rv: 5′CGGCTTCATGTCCATGTTC
KITLG_fw: 5′GCCAAGTCTTACAAGGGCAG
KITLG_rv: 5′GAAACTCTCTCTCTTTCTCTTGC
MRC1_fw: 5′CCT CGG ACC TGG TTA GGG
MRC1_rv: 5′GGATGTGTGGTCCTCCTTGG
ELISA
Concentrations of p40 (IL-12B/IL-23) in cell culture
supernatants were determined using an ELISA Kit from
BioLegend/Biozol (Eching, Germany) according to the
instructions of the manufacturer. IFNγ, IL-6 and IL-10
levels in ascites were quantified by ELISA kits purchased
from eBioscience (Frankfurt, Germany).
RNA sequencing (RNA-Seq)
RNA isolation and RNA-Seq was carried out on an
Illumina HiSeq 1500 as described [21]. Genome assem-
bly and gene model data were retrieved from Ensembl
revision 81. Sequencing data were deposited at EBI
ArrayExpress (accession numbers E-MTAB-5199 and
E-MTAB-4162).
Statistical analysis of experimental data
Paired and unpaired t tests were carried out with the
Python functions scipy.stats.ttest_rel () and scipy.stats.t-
test_ind (), respectively. Results were expressed as
follows: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
Confidence intervals were calculated using the bootstrap
method. Further statistical analyses were performed using
the Python functions numpy.percentile () and pandas.-
DataFrame.boxplot ().
Analysis of RNA-Seq data
RNA-Seq data was aligned to Ensembl v81 using STAR
(version 2.3.1z13_r470) and processed as reported [21].
The number of mapped reads was in the range of
19.74–35.92 million (median 29.42 million). TPM (tran-
scripts per million) values were calculated based on the
total gene read counts and length of merged exons and
corrected for contamination by tumor cells as described
[21]. The source code for implementing the algorithm
for TPM correction has also been deposited at GitHub
(https://github.com/IMTMarburg/rnaseqmixture). Genes
were considered expressed if they had a minimum TPM
value of 3. TAM samples with TPM >50 for EPCAM or
MSLN were excluded due to presumed tumor cell con-
tamination. All genomic sequence and gene annotation
data were retrieved from Ensembl release 81, genome
assembly hg38.
PCA and delineation of differentially expressed gene
clusters
PCA was carried out on using the sklearnPCA(n_compo-
nents = 2, whiten = True) and sklearn_pca.fit_transform ()
functions (Python) on RNA-Seq data. Pearson correlation
coefficients (r) were determined with scipy.stats.pearsonr
(). The Bioconductor package edgeR [24] was used for the
delineation of high variance gene clusters differentially
regulated in subgroups of TAMs identified by PCA (sig-
natures 1 and 2).
Coexpression analysis
Genes with the greatest expression variance were identi-
fied by pandas.DataFrame.var (). Pearson correlation
coefficients (r) were determined for the 3000 top genes
using scipy.stats.pearsonr (). Sets of genes with r > 0.89
and n > 10 were combined (n = 629) and analyzed by hier-
archical clustering using the scipy.cluster.hierarchy func-
tions linkage (method = “weighted”, metric = “correlation”)
and dendrogram (truncate_mode = “none”, color_threshold
= 0.8). The resulting 4 clusters (I, II, III, IV) were ana-
lyzed for intersections the signatures identified by
PCA (see above), which revealed close relationships of
cluster I with signature B and cluster III with signa-
ture A.
Pathway analyses
Gene sets were analyzed for Upstream Regulators using the
Ingenuity Pathway Analysis (IPA) database (Qiagen Red-
wood City, CA, USA) as described [22]. Functional annota-
tions were performed by gene ontology (GO) enrichment
analysis (http://geneontology.org).
Survival analyses
Overall survival (OS) data were retrieved from PRECOG
(https://precog.stanford.edu) [25]. Associations between
gene expression and relapse-free survival (RFS) were ana-
lyzed by the web-based tool “KM Plotter” [26] (http://
kmplot.com) using the following settings: ‘auto select best
cutoff ’, probe set option: ‘JetSet best probe’, histology:
serous, datasets: all; other settings: default.
Results
Clustering of ovarian carcinoma TAM samples
The transcriptomes determined for 18 independent sam-
ples of TAM isolated from the ascites of ovarian cancer
patients (Additional file 2: Dataset S1) were analyzed for
potential similarity patterns by different approaches, as
schematically summarized in Fig. 1. These samples were
selected for very low contamination with tumor cells, as
indicated by low TPM values (<50) for the epithelial
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marker genes EPCAM and MSLN. Furthermore, we ex-
cluded all genes (n = 13) highly expressed in tumor cells
or T cells versus TAMs (>100-fold) to minimize interfer-
ence by contaminating cells.
Genewise normalized TAM transcriptomes were used
for the bioinformatic delineation of similarity patterns.
Principal component analysis (PCA) did not yield a clear
partitioning of TAM samples into subgroups, although
eigenvalues suggested that the first two components can
explain most of the data. We therefore additionally
grouped samples according to the expression of CD163,
previously established as a TAM marker associated with
a poor clinical outcome of ovarian cancer [16]. Combining
PCA with the the expression pattern of this surrogate
marker revealed two discernible subgroups (A and B;
Fig. 2a), which was confirmed by Pearson correlation
(Fig. 2b) and distance-based multidimensional scaling
analysis (Additional file 3: Figure S1). Two other
markers associated with pro-tumorigenic functions, i.e.,
IL6 (interleukin 6) [14, 16–21, 27] and PCOLCE2 (pro-
collagen C-endopeptidase enhancer 2; see Additional
file 3: Figure S2), showed a very similar pattern of expres-
sion, except for IL6 expression in TAM117 (Fig. 2c-e).
Based on this data we defined subgroup A as TAM90,
TAM91, TAM101, TAM103, TAM104 and TAM105 ex-
pressing CD163, PCOLCE2 and IL6 at high levels relative
to the subgroup B samples TAM80, TAM82, TAM112,
TAM114, TAM116 and TAM118. These subgroups were
confirmed by flow cytometry showing a significantly
higher fraction of CD163+ and CD163+CD206+ cells in
subgroup A versus subgroup B TAMs, which was not
observed for other macrophage markers (Fig. 2f).
Taken together, these data indicate that cluster A TAMs
are skewed towards alternative activation (CD163), extra-
cellular matrix (ECM) remodeling (PCOLCE2) and pro-
motion of tumor growth (IL-6). As these markers are
associated with a short relapse-free survival, it is likely that
cluster B is linked to a favorable clinical outcome. This
conclusion is supported by the observation that the ascites
concentrations of IL-10, highly predictive of a poor sur-
vival of ovarian cancer [21, 28] was consistently and
dramatically increased in subgroup A versus subgroup
B patients (Fig. 2g). A similar pattern was observed
with IL-6 (with one outlier; Fig. 2g), also associated
with a short time to relapse [17, 18, 21].
Cluster-specific gene expression
To gain more insight into the specific phenotypes of
subgroup A and B TAMs, we analyzed the RNA-Seq
data sets with edgeR, a Bioconductor package for reliable
gene-specific dispersion estimation in small datasets
[24]. The edgeR tool identified a group of 932 genes dif-
ferentially expressed in the two subgroups of TAMs with
an FDR of <0.05 (Additional file 1: Table S1; Fig. 3a;
Additional file 2: Dataset S2). Of these, 329 genes were
upregulated in subgroup A versus B, and 603 genes
showed the opposite pattern (Fig. 3a; Additional file 2:
Datasets S3 and S4). These gene sets were termed signa-
ture A and signature B. In contrast to these protein coding
RNAs, edgeR did not identify any differentially expressed
Fig. 1 Schematic representation of data analysis and summary of results. Nomenclature for designation of clusters: TAM samples clustered by
PCA: letters (A, B); genes clustered by coexpression analysis: roman numbers (I, II, III). Genes identified by edgeR and upregulated in TAM subgroup
A or B were defined as signature A and B, respectively
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lncRNAs (FDR <0.05) in our RNA-Seq data set (annotated
lncRNAs: n = 7527).
Gene ontology (GO) enrichment analysis identified
significant associations of signature A with diverse bio-
logical processes, including ECM remodeling, locomo-
tion, endocytosis as well as lipid and carbohydrate
catabolism (Fig. 3b). In contrast, innate immune defense
mechanisms, T cell activation and IFN signaling were
strongly associated with signature B (Fig. 3b). Consistent
with these findings, Ingenuity Upstream Regulator Ana-
lysis indicated that signature B genes are major targets
of proinflammatory pathways triggered by lipopolysac-
charide (LPS), tumor necrosis factor α (TNF) and INFγ
(Fig. 3c), with all three target gene sets showing strong
overlaps (Additional file 3: Figure S3).
The differential expression patterns of signature A
and B genes are shown in Fig. 3d and Additional file 3:
Figure S4 for the IFN and ECM gene sets identified by
GO enrichment analysis as representative examples. As
expected, these gene sets showed opposite patterns of
regulation and the subgroup-selective expression was
clearly significant for the vast majority of genes (n = 48
out of n = 51). The RNA-Seq data for several genes
identified by edgeR were confirmed by RT-qPCR
(Fig. 3e).
Taken together, these observations point to a relatively
high complexity of biological functions affected by signa-
ture A genes, while the role of signature B genes appears
to be specifically associated with IFN-stimulated im-
mune defense mechanisms.
Confirmation of clustering by coexpression analysis
To obtain independent evidence for the robustness of
the clusters defined by PCA and edgeR we performed
coexpression analysis the genes showing the highest
variance across all TAM samples. Pearson correlation
and hierarchical clustering yielded three large clusters of
coregulated genes (Fig. 4a; Additional file 3: Figure S5;
Fig. 2 Clustering of ovarian carcinoma TAM samples based on RNA-Seq data. a Principal component analysis (PCA) of TAM transcriptomes. Samples
with high expression of CD163 (TPM>median) are shown in red (sub A), samples with low expression of CD163 in blue (sub B). b Heatmap based on
Pearson correlation coefficients (r) calculated for the TAM transcriptomes identified by PCA (sorted by subgroups). c-e Expression of IL6, PCOLCE2 and
CD163 in TAM samples of clusters A (red) and B (blue). Dotted lines show the quantiles used in panel (a). f Flow cytometry analysis of cluster A and B
samples. The plot shows the fraction of CD16+, CD32+, CD64+, CD163+, CD206+ and CD163+CD206+ cells (of CD14+ cells). g Concentrations of IL-6
and IL10 in the ascites of cluster A and B patients determined by ELISA. Boxes show the upper and lower quartiles, whiskers the 95% confidence
intervals (CI), and horizontal lines the median. Asterisks indicate the statistical significance determined by unpaired t test (cluster A versus B
samples). n/a, not applicable since all values >97%; ns: not significant
Adhikary et al. BMC Genomics  (2017) 18:243 Page 5 of 14
Additional file 2: Datasets S5-S7). Hierarchical clustering
of TAM samples using a combined set of these
genes (Fig. 4a) yielded the identical partitioning into
subgroups A and B as the PCA-based approach in
Fig. 2a. Consistent with this observation, two of these
gene clusters showed substantial and specific overlaps
with signatures A and B, respectively, i.e., cluster I with
signature A (120/140 = 85,7% and no overlap with signa-
ture B); cluster III with signature B (148/266 = 55.6%
and no overlap with signature A), as shown in Fig. 4c as
well as Additional file 2: Datasets S8 and S9.
Functional annotations revealed endocytosis and
chemotaxis for cluster I, chromatin modification and
splicing for cluster II, and immune defense and
interferon signaling for cluster III (Fig. 4d). Consistent
with the overlaps of described in the preceding para-
graph, the GO terms for cluster I were also found for
signature B, and the terms for cluster III correspond to
those for signature A (compare Figs. 3b and 4d).
Finally, expression of cluster I genes was higher in
subgroup B versus subgroup A (Fig. 4e), and vice versa,
expression of cluster III genes was higher in subgroup A
relative to subgroup B (with the exception of TAM101
(Fig. 4g). In contrast, no differential expression was ob-
served for cluster II genes (Fig. 4f ). Taken together, these
findings clearly suggest that cluster III corresponds to
signature A, while cluster I corresponds to signature B.
Thus, both strategies, PCA of patient samples followed
Fig. 3 Identification of differentially expressed genes in subgroup A versus B TAMs by edgeR. a Scatter plot showing the expression of genes
identified by the edgeR tool (FDR <0.05) in TAM subgroups A or B identified by PCA in Fig. 2. Data represent the ratio (FC) of median TPM
values for subgroup A versus subgroup B. b Functional annotation of genes upregulated in subgroup A (red) or subgroup B (blue) by gene
ontology (GO) enrichment analysis. p values are plotted against fold enrichment. Only specific non-redundant terms with p values <0.01 and
enrichment >3 are shown. c Upstream Regulator Analysis (Ingenuity Pathways Analysis database) of upregulated genes with p < 10−8. d Expression of
the IFN signaling-associated genes of signature B identified by GO enrichment analysis (c). Boxes show the upper and lower quartiles, whiskers
the 95% CI, and horizontal lines the median. e Validation of RNA-Seq data. Analysis by RT-qPCR of signature A and B genes (Additional file 2:
Datasets S3 and S4) in TAM samples from subgroup A and B (n = 6). Error bars show the standard deviation and horizontal lines the mean. Red:
cluster A samples; blue: cluster B samples. Asterisks indicate the statistical significance determined by unpaired t test (cluster A versus B samples);
ns: not significant
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by edgeR and coexpression analysis of high variance
genes yielded very similar results, and identified IFN sig-
naling as a hallmark of signature B upregulated in sub-
type B TAMs.
Association of signature B, interferon signaling and
survival
In order to identify potential associations between the
expression of this genes in ovarian cancer with clinical
outcome we made use of the PRECOG database, which
contains the results of a meta-analysis of 1763 patients
from 12 studies [25]. These studies used solid ovarian
tumor tissue containing substantial amounts of myeloid
cells [25, 29] for transcriptome analysis, suggesting that
the PRECOG data are also suitable for testing survival
associations for genes expressed in abundant tumor-
associated host cells, such as TAMs.
Signature A, cluster III and their overlap comprised
similar fractions of genes associated with poor or favorable
OS (Fig. 5a and top panel in Additional file 3: Figure S6).
Only when genes with distinct functional annotations
were analyzed separately a clear OS association was
detectable. Thus, signature A genes linked to ECM re-
modeling were strongly associated with a short OS
(Fig. 5a and Additional file 3: Figure S7). In contrast,
signature B, cluster I and their overlap were clearly
linked to a favorable clinical outcome (Fig. 5a and bottom
panel in Additional file 3: Figure S6). This applied in
particular to the IFN signaling-associated genes of sig-
nature B, as shown in detail in Fig. 5b. A similar inverse
association with relapse-free survival was also found
based on data from the KM plotter database, as exem-
plified for IRF1 and TAP1 in Fig. 5c and d. All PRECOG
z-scores for signature A and B genes are also listed in
Additional file 2: Dataset S10.
These associations with a favorable clinical course are
not simply consequence of the extent of myeloid cell
infiltration. First, activation state-independent myeloid
Fig. 4 Coexpression analysis of all TAM samples. a Correlation based heatmap of gene clusters (I, II and III; 265, 222 and 139 genes, respectively)
defined by coexpression analysis of genes with the highest variance across all TAM samples, followed by hierarchical clustering (see Additional
file 3: Figure S4 for a dendrogram). b Hierarchical clustering of patients based on the genes identified in panel (a). c Overlap of genes in clusters
I - IV with signatures A and B identified by PCA. d Functional annotation of cluster I (blue), cluster II (green) and cluster III (red) genes by gene
ontology (GO) enrichment analysis. p values are plotted against fold enrichment. Only specific non-redundant terms with p values <0.0001 and
enrichment >3 are shown. e Expression of cluster I genes (n = 120; genewise normalized TPM values) in subgroup A (red) and B (blue) samples.
f As panel (e), but for cluster II genes (n = 223). g As panel (e), but for cluster III genes (n = 148). Boxes show the upper and lower quartiles,
whiskers the 95% confidence intervals (CI), and horizontal lines the median
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marker genes, such as CD14 or CD68 did not show any
significant association with ovarian cancer OS (PRE-
COG) [25] or RFS [26] (Fig. 5e and f). Second, tumor infil-
tration by myeloid cells inferred from RNA expression
data (CIBERSORT) [29] showed no significant association
with OS, with a trend towards a worse clinical outcome
for monocytes (Additional file 3: Figure S8). Third, a num-
ber of the IFN signaling-associated genes of signature B
are expressed at high levels (TPM> 10) selectively in
TAMs compared to tumor cells or tumor-associated CD3
Fig. 5 Association of cluster-specific gene expression with ovarian cancer survival. a Mean z-scores (OS) for signature A and B genes; the ECM-related
and IFN signaling-associated genes of signature A and B, respectively; cluster III and I genes; and genes representing the intersection of signature A
with cluster III or of signature B with cluster I. Survival data were obtained from the PRECOG database with 1763 ovarian cancer patients [25]. b OS
z-scores for signature B genes that are associated with IFN signaling. Significant associations with a favorable clinical outcome are shown in
blue (z-score < −2.0; HR <1). The corresponding data for the complete signatures A and B are shown in Additional file 3: Figure S6. c-f Kaplan-Meier
plots analyzing the association of IRF1, TAP1, CD14 and CD68 with RFS of high-grade serous ovarian cancer determined by KM plotter [26].
g Expression of the signature B genes HLA-DPB1, HLA-DRA and KYNU in TAMs (blue, n = 33), tumor cells (red, n = 15) and CD3+ TATs (green,
n = 5) isolated from ovarian cancer ascites
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+ lymphocytes (TATs) isolated from ovarian cancer ascites,
as exemplified by HLA-DRA, HLA-DPB1 and KYNU in
Fig. 5g).
Expression of IFN-encoding genes is linked to ovarian
cancer survival
Analysis of the PRECOG database also revealed a signifi-
cant association of IFNG expression with a longer sur-
vival (z < −2; Fig. 6a). Similar associations were also
found for several genes coding for type I IFNs, i.e.,
IFNA1, IFNA2, IFNA14 and IFNB1. Evaluation of RNA-
Seq data for different cell types [21] (Additional file 2:
Dataset S1) showed that tumor-associated T cells (TATs)
express IFNG at relatively high levels (TPM= 10–100),
while TAMs and tumor cells do not (Fig. 6b). Interest-
ingly, all TAT samples expressed IFNG at higher levels
than normal CD3+ T cells isolated from the blood of
healthy donors, with >10-fold higher levels observed with
three out of the five patients analyzed. It is therefore likely,
that partially activated TATs are a major source of IFNγ
within the tumor microenvironment and the malignancy-
associated ascites. This is consistent with the presence of
readily detectable IFNγ levels in the ascites of a subgroup
of patients (n = 21 above ELISA detection limit out of a
total of n = 61 samples; Fig. 6c). By contrast, all type I IFN
genes associated with a favorable OS were expressed a
very low levels by all three cell types, if at all (Additional
file 3: Figure S9).
IFNγ prevents the ascites-induced IL12B activation block
in macrophages
Interleukin-12 (IL-12) is a particularly interesting cyto-
kine in the context of ovarian cancer due to its immune
stimulatory anti-tumor effects and its inverse associa-
tions with disease progression patients [30–32]. A hall-
mark of TAMs in ovarian cancer ascites is their defect
to release IL-12 in response to inflammatory stimuli,
which results from a transcriptional block of the IL12B
Fig. 6 Associations of IFN gene expression with survival and abrogation by IFNγ of the ascites-induced IL12B activation block. a z-scores for the
association of IFN genes with OS (PRECOG data). Blue bars: significant associations with a favorable clinical outcome (z-score < −2.0; HR <1). b
Expression of IFNG in TAMs (n = 33), tumor cell (n = 22) and TATs (n = 5) samples from ovarian carcinoma ascites, and in CD3+ T cells from healthy
donors (n = 2). Each dot represents an individual sample (see Additional file 2: Dataset S1 for details). c IFNγ concentrations in the ascites from
n = 61 ovarian cancer patients determined by ELISA. d IL12B expression in MDMs differentiated for 6 d either in RPMI plus 5% human A/B serum
(R5 medium) or in ovarian cancer ascites in the absence or presence of IFNγ (50 ng/ml). Cultures were stimulated with LPS (100 ng/ml) plus IFNγ
(20 ng/ml) or solvent only (Ctrl) for 24 h and RNA was analyzed by RT-qPCR. The experiment was performed with 7 independent samples (combinations
of 5 donors and 5 ascites samples). e p40 (IL-12B/IL-23) protein concentrations in the culture medium of the experiments in panel (d). Each dot represents
an independent sample. Horizontal lines: median. Significance was determined by t-test between unstimulated and IFNγ+ LPS-stimulated cells
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gene encoding the p40 subunit [14, 33, 34]. Another
cytokine with beneficial immune stimulatory and anti-
tumor effects in ovarian cancer patients is IFNγ [35–38],
consistent with the observation that IFNγ can prevent
the skewing of monocyte differentiation by ovarian can-
cer ascites from immunostimulatory IL-10lowIL-12high
macrophages to TAM-like IL-10highIL-12low cells [34].
To assess the relevance of the IFN signaling-associated
signature B we explored the relationship between IL-12
and IFNγ in further detail.
Toward this end, we measured the inducibility of IL12B
mRNA by lipopolysaccharide (LPS) plus IFNγ in
monocyte-derived macrophages that were differentiated
either in the presence of regular cell culture medium (R5)
or in ascites, both in the absence or presence of IFNγ dur-
ing macrophage differentiation. As expected, all ascites
samples tested blocked IL12B induction, which, however,
was almost completely prevented by IFNγ (Fig. 6d). In full
agreement with these findings, secretion of p40 was
strongly induced by LPS plus FNγ in R5, which was
blocked by ascites only in the absence of IFNγ during dif-
ferentiation (Fig. 6e). These results clearly point to a clin-
ically beneficial IFNγ – p40/IL12B axis in differentiating
myeloid cells in the ovarian cancer microenvironment,
thus providing a potential explanation for the association
of subgroup B TAMs with clinically favorable parameters.
Discussion
Delineation of subgroups of TAMs
Transcriptional signatures of TAMs distinguishing sub-
groups of patients in a biologically or clinically meaning-
ful way have not been reported to date. We have used
the ovarian cancer-associated ascites as an experimental
system to address this issue by an unbiased approach
(Fig. 1). By applying PCA to data derived by next gener-
ation sequencing we were able to split TAM samples
from different patients into subgroups characterized by
distinct gene expression patterns (Fig. 2). Remarkably,
cluster B is basically congruent with the subgroup of
patients with low expression of the IL6, PCOLCE2 and
CD163 genes, a low fraction of anti-inflammatory
CD163+/CD206+ TAMs and low ascites concentrations
of IL-10 and IL-6 (Fig. 2c-g). These features are known
as negative prognostic factors for different tumor entities,
including ovarian cancer [16–18, 21, 28, 39, 40]. The same
subgroups were also identified by an another unbiased
approach, i.e., coexpression analysis of all TAM samples
(Fig. 4). Therefore, these findings clearly suggest that
subgroups A and B represent patients with a poor and
favorable clinical outcome, respectively.
IFN signaling is a hallmark of signature B TAMs
Intriguingly, a hallmark of subgroup B is the upregula-
tion of target genes of the IFN signaling network (Figs. 3b
and 4d). Consistent with this finding, our analysis of the
PRECOG database revealed a strong association of these
genes with a longer OS (Fig. 5b). This is in agreement with
previous studies which associated a high protein expression
of several IFN signaling components with a favorable clin-
ical outcome, including IRF1 [41]. Furthermore, IFNγ in-
clusion in the first-line therapy of ovarian cancer resulted
in an effector immune cell response [35] and a prolonga-
tion of progression-free survival [36, 37], while type I IFNs
had no benefit [42]. In keeping with these observations, ele-
vated IFNG expression in ovarian cancer tumor tissue cor-
related with an improved clinical outcome in patients [43].
Our upstream regulator and functional annotations
(Figs. 3b, c and 4c) yielded IFNγ and type I IFN as acti-
vated signaling pathways. We attribute this apparent am-
biguity to the fact that type I and II target genes show
substantial overlaps. Type I IFNs signal through their
common receptor complex via JAK1/TYK2 to the hetero-
trimer ISGF3 (STAT1:STAT2:IRF9) and, to a lesser extent,
through STAT1 homodimers, whereas IFNγ, the single
type II IFN, uses only STAT1 homodimers phosphorylated
by IFNγ receptor-associated JAK1/JAK2 [44]. Further-
more, STAT-independent pathways could be activated
differentially by the different receptor complexes. Taken
together, this explains the overlapping, but not identi-
cal, effects of the two types of IFNs. Interestingly, JAK2
is among the signature B genes identified in this study
(Fig. 3d, Additional file 2: Dataset S4) and might thus
contribute to IFNγ-mediated effects. Taken together
with our observation that, in contrast to IFNG (Fig. 6b),
none of the type I IFN genes associated with a longer
OS is expressed at significant levels by TAMs, TATs or
tumor cells (Additional file 3: Figure S9) it is conceivable
that upregulation of the IFN target genes of signature B is
due to activated IFNγ signaling.
Collectively, these findings suggest that the increased
expression of IFN target genes in cluster B TAMs results,
at least in part, from an elevated level of IFNγ in the
tumor microenvironment. Of note, a substantial fraction
of the IFN signature genes upregulated in cluster B TAMs
are also target genes of pro-inflammatory pathways
(Additional file 3: Figure S3). This suggests that other
cytokines present in ascites, notably TNFα [45], might
contribute to the induction of these genes. This would
be consistent with the prevailing opinion that pro-
inflammatory macrophages inhibit tumor progression.
Since RNA-Seq measures mean transcript levels within
a cell population, the fraction of TAMs expressing a
given signature cannot be determined. It is therefore
possible that elevated expression of IFN genes reflects
the higher relative occurrence of a subpopulation of
cells. These might be a newly recruited, CD163-negative,
monocyte-like TAM subset similar to the macrophage
fraction that is able to elicit inflammatory responses in
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immune privileged reproductive organs [46]. This
hypothesis is in agreement with the flow cytometry data
in Fig. 2f, indicating that CD163+ and CD163− cells
occur in both subgroup A and B, even though their ratio
is clearly different in both subpopulations. Likewise, it is
possible that a few TAM samples could not be fitted into
either subgroup (Fig. 2a) due to the presence of similar
fractions of functionally different subpopulations.
Role of T cells
Ascites contains substantial numbers of different types
of T cells, in particular CD4+ and CD8+ cells [47, 48],
known as important IFNγ producers under physio-
logical conditions. A functional role of T cells in
ovarian cancer is supported by many published obser-
vations strongly associating infiltrating T cells with a
longer survival, with a high ratio of CD8+ versus regu-
latory T cells having a strong impact [47–49]. Consist-
ent with these findings, transcriptome analyses defined
distinct high-grade serous ovarian carcinoma subtypes,
of which the immune reactive subtype was associated
with the best prognosis [50]. Transcriptome profiling
also identified several genes contributing to cytotoxic
T lymphocyte recruitment as being differentially
expressed in tumors with high versus low CD8 T cell
infiltration, including IRF1 [51–53], providing another
link between T cells, IFNγ and a favorable clinical out-
come. Furthermore, the analysis in Fig. 6a revealed a
positive impact of IFNG expression on ovarian cancer
OS. It is thus possible that IFNγ in the tumor micro-
environment and the expression of IFN target genes in
TAMs are indicators of the presence of activated, IFNγ
secreting T and/or NK cells mediating anti-tumor
immune responses.
Our RNA-Seq data support the conclusion that TATs
are a major source of IFNγ in ascites (Fig. 6b). Since
TATs showed a considerably higher level of IFNG ex-
pression compared to normal T cells, it is likely that
the former are partially activated, at least in a subset of
patients. This would be consistent with the observed
clonal expansion of T cell subpopulations of unknown
biological relevance in ovarian cancer ascites [54].
However, TATs apparently are not functional with re-
spect to an anti-tumor response, as suggested by pro-
gression of the disease, presumably due the inhibitory
effect of ascites on T cell activation [55]. In line with
this conclusion other makers of an activated TH1, TH2,
TH9 or TH17 response were only weakly upregulated
in a subset of TATs relative to normal T cells (e.g.,
FASLG, GZMA, TNF), expressed at similar levels in
both (e.g., CCR4, IL10, LAMP1/CD107A, LTA, PRF1) or
not expressed at all (e.g., IL2, IL4, IL9, IL12B, IL13,
IL17A) (Additional file 2: Dataset S1).
Inflammatory signaling and IL-12 induction
There is a large body of evidence to suggest that IFNγ
and IL-12 are key determinants of a beneficial immune
response in many cancers [56]. Physiologically, IL-12 is
released by macrophages and other antigen-presenting
cells in response to proinflammatory signals, including
toll-like receptor ligands and IFNγ from T or NK cells.
IL-12 in turn stimulates a cytotoxic response by indu-
cing multiple immune stimulatory processes, including
the differentiation of naive T cells into Th1 cells, the
activation of CD8 + T cells and the maturation or activa-
tion of NK cells [57].
Multiple observations strongly support the hypothesis
that IL-12, and probably its induction by IFNγ, are
crucial determinants of ovarian cancer outcome. For ex-
ample, IL-12 locally produced significantly delayed peri-
toneal disease development in a mouse model [32],
engineered tumor-targeted T cells ectopically expressing
a fused IL12A/IL12B cDNA have been reported to eradi-
cate ovarian tumors in vivo [31] and a highly significant
association was found between high IFNG and IL12B
expression and a more favorable clinical outcome of
advanced stage ovarian carcinoma [30].
In TAMs, the acquisition of a proinflammatory
phenotype, including the secretion of IL-12, in response
to proinflammatory signals is non-functional. In LPS-
stimulated murine macrophages, Il12b induction is se-
lectively dependent on the NFκB family member Rel
[58] and on TLR signaling-induced chromatin remodel-
ing which is independent of Rel [59]. Furthermore,
IFNγ has been shown to enhance the synthesis of IL-12
by priming macrophages for LPS-mediated induction of
the IL12B gene [60]. Finally, the nuclear accumulation
of a NFκB p50 homodimer with presumed inhibitory
function has been suggested for the acquisition of a
TAM phenotype characterized by the defective produc-
tion of IL-12 [33]. Intriguingly, IFNγ can prevent the
inhibitory effect of ascites on the inducibility of IL12B
in macrophages (Fig. 6d, e), consistent with a previous
report that IFNγ was able to shift monocyte differenti-
ation from TAM-like cells to pro-inflammatory macro-
phages [34]. It is currently unclear if, and if so how,
TLR pathways, IFNγ triggered STAT signaling, chroma-
tin remodeling and p50 accumulation functionally
interact in the regulation/dysregulation of the IL12B
gene in either normal macrophages or TAMs. Understand
these connections will be crucial to be able to explore the
potential of the IFNγ – IL-12 axis in stimulating cytotoxic
immune responses and assess potential applications.
Conclusions
In the present study, we have address the question as to
whether associated-derived TAMs from different
patients with ovarian cancer represent a continuum of
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overlapping transcriptomes or can be categorized into
phenotypically distinct groups on the basis of their glo-
bal gene expression patterns. The results of both princi-
pal component analysis (PCA) and coexpression analysis
clearly demonstrated that the latter is the case, and lead
to the definition of two highly distinct subgroups of pa-
tients differing in the expression of genes associated with
cytokine signaling, immune regulation and extracellular
matrix reorganization. One of the two subgroups identified
(subgroup A) is associated with a high expression of
protumorigenic, immunosuppressive and clinically un-
favorable markers, including IL-6, IL-10, CD163 and
PCOLCE2. By contrast, the second subgroup is charac-
terized by the upregulation of genes linked to IFN sig-
naling and associated with a longer survival. Expression
of this IFN-related signature also showed a striking link
to a longer survival, and IFNγ abrogated the inhibitory
effect of ovarian cancer ascites on the inducibility of IL-
12 in cultured macrophages. As IL-12 is a key mediator of
a cytotoxic immune response, this finding provides a
possible explanation for the link of the IFN signaling-
associated signature B to ovarian cancer survival.
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